News

Fairway Medical Technologies To Develop Biosensor For Blood Pathogens And Warfare Threats

Fairway Medical Technologies, Inc. has received a $900,000, 3-year contract from the Department of the Navy to apply its optoacoustic technology to the real-time detection of blood borne pathogens and biological warfare agents under battlefield conditions. This grant is part of a larger, $3 million project led by Prof. Randolph Glickman, Principal Investigator from the University of Texas Health Science Center (UTHSC) at San Antonio.

The grant, entitled "Rapid identification of pathogenic agents in biological samples using pulsed laser optoacoustic spectroscopy with targeted nanoparticle contrast agents," will be carried out as a collaborative project between UTHSC, Fairway Medical Technologies and the Naval Health Research Center Detachment Directed Energy Bioeffects Laboratory at Brooks City-Base.

Fairway Awarded $3.8 Million Federal Funding for Phase II Research Using Optoacoustic Technology for Early Cancer Detection

New federal funding totaling $3.8 million will support Phase II research into breast and prostate cancer detection using a laser optoacoustic imaging technology developed by Fairway Medical Technologies.

“Prostate cancer strikes one in six men in America”
.The research funding includes authorization of two National Cancer Institute grants:

• A $2.7 million Phase II grant from The National Institutes of Health-National Cancer Institute (NIH-NCI) to further develop the imaging technology in laboratory animal tests, and to explore its use in attacking cancer tumor cells.

• A $1.1 million SBIR (Small Business Innovation Research) Phase II grant by the National Cancer Institute to develop a commercial medical imaging system for early detection of prostate cancer that is able to provide real time visualization of small prostate cancers and to guide prostate biopsy procedures.

The optoacoustic technology will be introduced as a real-time screening tool for breast cancer detection and diagnosis, an estimated $5.9 billion market in North America, by Seno Medical Instruments of San Antonio, which has purchased the technology and entered into a long-term development agreement with Fairway. Seno will also provide development funding for the technology’s initial commercialization steps.